Clinical trial of qHPV vaccine in HIV positive Men who have sex with men
| ISRCTN | ISRCTN14732216 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN14732216 |
| Secondary identifying numbers | PI-0619-2001 FPyS |
- Submission date
- 21/06/2016
- Registration date
- 02/08/2016
- Last edited
- 12/09/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English Summary
Background and study aims
As HIV-infected patients are living longer, non-AIDS-defining cancers (cancers which do not indicate the development of AIDS) are becoming much more common. Anal squamous cell carcinoma (ASCC) is one of the most common non-AIDS-defining cancers found in men who have sex with men (MSM). Around 90% of cases happen in individuals with a human papilloma virus (HPV) infection, the lesions (wounds) of which in the anal canal (back passage) are considered to increase risk of developing ASCC. One possible way to address this is to prevent HPV infections using the HPV vaccine. The aim of this study is to find out whether the HPV vaccine (qHPV) can help prevent the development of lesions in the anus that could lead to anal cancer.
Who can participate?
HIV positive adult MSM who have an anal infection caused by HPV.
What does the study involve?
Participants are randomly allocated to one of two groups. Those in the first group receive injections of the qHPV vaccine into their shoulder muscle (deltoid muscle) at the start of the study and then three and six months later. Those in the second group receive placebo (dummy) injections into their shoulder muscle (deltoid muscle) at the start of the study and then three and six months later. For all participants, the injections are in the same arm each time. Participants undergo a scan of their anal canal to see whether there are any lesions so that the effectiveness of the vaccine can be assessed at the start of the study and then after 12, 24, 36 and 48 months. At the start of the study and then two and six months after each vaccination, participants complete a questionnaire about any side effects they have experienced as well as providing a blood sample.
What are the possible benefits and risks of participating?
Participants benefit from receiving screening, diagnosis and treatment of their HPV infection. Those who receive the qHPV vaccine could also benefit from continued protection against HPC infections and associated lesions which could develop into ASCC. There are no notable risks involved with participating in the study.
Where is the study run from?
University Hospital Virgen de las Nieves (Spain)
When is the study starting and how long is it expected to run for?
November 2011 to May 2017
Who is funding the study?
Progress and Health Foundation, Ministry of Health and Social Welfare (Spain)
Who is the main contact?
Dr Carmen Hidalgo Tenorio
pgcheca@ugr.es
Contact information
Scientific
Infectious Disease Service
Complejo Hospitalario de Granada
University Hospital Virgen de las Nieves
Av fuerzas armadas nº2
Granada
18014
Spain
 ORCID ID |
0000-0002-6394-5728 |
|---|---|
| Phone | +34 (0)627010441 |
| pgcheca@ugr.es |
Study information
| Study design | Double-blind parallel-group randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | Efecctiveness of of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men having sex with men (MSM): a double-blind randomised clinical trial |
| Study hypothesis | The tetravalent vaccine of HPV administered to patients MSM infected with HIV, not colonized by the serotypes administered in the vaccine, will produce a reduction in the incidence and progression of dysplastic lesions (AIN, carcinoma) of the anal mucosa, which will modify the protocols of screening of lesions and an improvement in the quality and expectations of these patients. |
| Ethics approval(s) | Comité de ética de la investigación de centro Granada, 26/03/2012 |
| Condition | Anal cancer related with HPV and HIV positive MSM |
| Intervention | Participants are randomised to one of two groups using Epidat 3.1 software: Vaccine group: Participants receive injections of 0.5ml Quadrivalent (HPVs 6/11/16/18) vaccine into the deltoid muscle at the baseline, 3 and 6 month study visits. All doses are competed in the same arm. Placebo group: Participants receive injections of 0.5ml placebo into the deltoid muscle at the baseline, 3 and 6 month study visits. All doses are competed in the same arm. Follow up for all participants (at 12, 24, 36 and 48 months) involves the recording of clinical-epidemiological variables, blood analyses (full blood haemogram and blood chemistry analytes were measured, together with CD4, CD8 lymphocytes counts, and HIV viral load (VL)), PCR of the HPV and anal cytology, high-resolution anoscopy (HRA), and testing for antibodies against the 4 genotypes of the qHPV vaccine. |
| Intervention type | Biological/Vaccine |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Not provided at time of registration |
| Primary outcome measure | Efficacy of the qHPV vaccine is assessed through the development of HSIL or anal cancer in anal mucosa using high resolution anoscopy at baseline and 48 months. |
| Secondary outcome measures | 1. Clearance of HPV genotypes in anal canal mucosa after vaccination is measured using PCR at baseline, 12, 24, 36 and 48 months 2. Prevalence of high squamous intraepithelial lesion (HSIL) and HR-HPV in the anal mucosa is measured using high resolution anoscopy at baseline, 12, 24, 36 and 48 months 3. The seroconversion to the four serotypes of HPV used after vaccination is measured using PCR at baseline, 12, 24, 36 and 48 months 4. Adverse effects after vaccination are measured using a purpose build questionnaire (including questions about pain, nausea, diarrhoea, rash, abdominal pain, pain at injection site) and blood testing (to determine if there are any kidney, liver, or muscle effects) at baseline, 2 and 6 months after each vaccination |
| Overall study start date | 30/11/2011 |
| Overall study end date | 12/05/2017 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Male |
| Target number of participants | Based on our own data, 67.2% of HIV MSM patients have a pathological anal biopsy and, of these, 29.8% have HSIL (≥AIN2) with a rate of infection by high-risk genotypes of 74.2% [29]. To demonstrate a reduction of at least 34% with the administration of the qHPV vaccine, with a statistical power of 98% and a level of significance of 5%, it is necessary to include 60 patients per group. |
| Participant inclusion criteria | 1. HIV-positive MSM patients 2. >18 years of age 3. Those who, at the time of inclusion into the study, had not been infected simultaneously by the 4 genotypes of HPV that the quadrivalent vaccine addresses 4. Patients who had high-resolution anoscopy (HRA) screening for inclusion are normal or had only condylomas and/or low squamous intraepithelial lesion (LSIL) in anal biopsy |
| Participant exclusion criteria | 1. HIV positive MSM (Men Who Have Sex with Men) 2. Simultaneous anal infection caused by the 4 genotypes addressed by the vaccine, or at least HPV16 3. Aged 18 years and over 4. Active opportunist infection at the time of recruitment into the study 5. Patients who, in screening anoscopy had HSIL, or ASCC or having received treatment for these lesions 6. History of allergy to aluminium and/or yeast extract excipient |
| Recruitment start date | 15/05/2012 |
| Recruitment end date | 15/05/2014 |
Locations
Countries of recruitment
- Spain
Study participating centre
Granada
18014
Spain
Sponsor information
Government
Avda. Américo Vespucio 5
Bloque 2, 2ª Planta
Parque Científico y Tecnológico Cartuja
Sevilla
41092
Spain
| Phone | +34 (0)955 04 04 50 |
|---|---|
| comunicacion.fps@juntadeandalucia.es | |
| Website | http://fps2.junta-andalucia.es/fundacionprogresoysalud/es |
"ROR" |
https://ror.org/0048t7e91 |
Funders
Funder type
Government
No information available
Results and Publications
| Intention to publish date | 31/12/2016 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Planned publication of study results in a peer-reviewed journal. |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 18/07/2017 | Yes | No | |
| Results article | results | 18/07/2017 | Yes | No | |
| Results article | 20/01/2021 | 12/09/2023 | Yes | No |
Editorial Notes
12/09/2023: Publication reference added.
25/07/2017: Publication reference added.
20/07/2017: Publication reference added.
